IMP

Imexpharm (IMP) undergoes board restructuring after Livzon Pharmaceutical Group acquired a 67.87% stake from SK Group and other shareholders. Two non-executive directors and one independent director resigned, with Livzon set to nominate replacements. AGG and OCB also announced senior leadership changes.

Imexpharm (IMP) sees three board members resign after Lian SGP Holding, a unit of China's Livzon Pharmaceutical Group, completed a VND 6,000B (USD 240M) acquisition of a 67.87% stake, becoming the new parent. The resignations include Chairman Woo Sungmin and signal a full management transition under new Chinese ownership.

Imexpharm (IMP) loses three board members including Chairman Woo Sungmin on May 18, 2026, with no stated reason, just weeks after Chinese group Livzon completed a VND 6,000B tender offer for 67.87% of IMP. The resignations signal a likely board overhaul under new controlling shareholder.

Imexpharm (IMP) has changed hands from Korea's SK Group to China's Livzon Pharmaceutical Group, which acquired a 67.87% controlling stake for approximately VND 6,000 billion. The deal, completed in early May 2026, values IMP at roughly VND 8,800 billion and marks a shift in foreign ownership for Vietnam's second-largest listed pharma firm by market cap.

Imexpharm (IMP) leaders including the CEO sold shares on May 7, 2026, following Livzon Group's acquisition of a 67.87% stake via Lian SGP Holding for nearly VND 6,000B (~$240M). The change in control from SK Group to a top-25 Chinese pharmaceutical firm signals a strategic shift for IMP.

Imexpharm (IMP) leaders, including the CEO and two deputy CEOs, sold a combined 619,400 IMP shares on May 7, shortly after Lian SGP Holding Pte. Ltd. acquired a 67.87% stake from SK Group for nearly VND 6,000 billion (USD 240 million), becoming the new parent company. The stake change signals a strategic shift under new Chinese ownership via Livzon Pharmaceutical Group.

Vietnam's top three pharma companies by market cap—DHG, IMP, and DHT—are now under foreign control or significant influence, with Taisho, Livzon, and ASKA as key shareholders. The sector is projected to double from $8-9 billion to $16 billion by 2032, driving M&A interest.

Livzon Pharmaceutical Group, via its subsidiary Lian SGP Holding, has acquired a 67.87% controlling stake in Imexpharm (IMP) for nearly VND 6,000 billion ($240 million). The deal, at VND 57,400/share, values IMP at VND 8,842 billion and is expected to boost the company's R&D and competitiveness.

Imexpharm (IMP) is now majority-owned by Livzon Pharmaceutical Group after Lian SGP acquired 67.87% of shares for ~VND 6,000B ($240M). The deal gives Livzon control of a top Vietnamese pharma company with EU-GMP facilities, positioning it to expand high-tech drug production and leverage Livzon's R&D capabilities.

Livzon Pharmaceutical Group, through its subsidiary Lian SGP Holding, has acquired a 67.87% stake in Imexpharm (IMP) for approximately VND 6,000 billion (USD 240 million) via a public tender offer at VND 57,400 per share. The deal marks a significant foreign acquisition in Vietnam's pharmaceutical sector, with Livzon committing to maintain IMP's operations and expand its high-tech product lines.

IMP: Chinese pharmaceutical group Livzon, via subsidiary Lian SGP Holding, has acquired a 67.87% stake in Imexpharm for nearly VND 6,000 billion (USD 240 million), becoming the controlling shareholder. The deal triggers exit by SK Group entities and some IMP leaders, who have registered to sell their shares. Livzon commits to maintaining IMP's strategy while expanding high-tech product lines on EU-GMP certified lines.

VNDirect (VND) posted Q1 2026 pre-tax profit of VND 681 billion, a 43% year-on-year increase, as part of a broader earnings release wave. TP Securities (ORS) led with a 1,961% surge to VND 42 billion, while ACBS grew 67% to VND 303 billion, highlighting divergent performance in Vietnam's securities sector amid mixed market conditions.

SK Group's subsidiary sold 61.8% of its stake in Imexpharm (IMP) in April 2026 for about $200 million, doubling its initial investment. Livzon Pharmaceutical Group concurrently acquired 67.87% of IMP for roughly VND 6,000 billion, marking a major M&A deal in Vietnam's pharma sector. The transaction underscores growing foreign interest in Vietnamese drug manufacturers with EU-GMP-certified facilities.